Related Experiment Videos
Hemodialyzability of sertraline
M H Schwenk1, M A Verga, J D Wagner
1St. John's University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, Jamaica, New York 11439, USA.
Clinical Nephrology
|August 1, 1995
Summary
Sertraline pharmacokinetics in end-stage renal disease (ESRD) patients undergoing hemodialysis were studied. Sertraline clearance is impaired in ESRD, suggesting dose adjustments may be needed.
Area of Science:
- Pharmacology
- Nephrology
- Psychiatry
Background:
- Sertraline is a selective serotonin reuptake inhibitor antidepressant.
- Pharmacokinetics of sertraline in end-stage renal disease (ESRD) and hemodialysis effects are not well understood.
Purpose of the Study:
- To investigate sertraline pharmacokinetics in anuric hemodialysis patients.
- To determine the impact of hemodialysis on sertraline clearance.
Main Methods:
- Two anuric hemodialysis patients received a 100 mg sertraline dose.
- Blood samples were collected pre- and post-dialysis, and hourly during dialysis.
- Dialysate was collected and assayed for sertraline using gas chromatography-mass spectroscopy.
Main Results:
- Sertraline absorption and distribution were similar to normal renal function subjects.
- Sertraline was not detected in hemodialysate, indicating no significant removal by dialysis.
- Elimination half-life was prolonged (42-92 hours) compared to normal (24-36 hours), suggesting impaired clearance.
Conclusions:
- Sertraline clearance is reduced in ESRD patients.
- Smaller sertraline doses may be necessary for ESRD patients.
- Post-hemodialysis sertraline supplementation is not required.